New hope for long COVID heart damage: trial tests combo therapy to halt progression
NCT ID NCT05619653
Summary
This study is testing whether a combination of two existing drugs can protect the heart in people with Long COVID who have developed heart inflammation. Researchers will give 279 participants either the active medication or a placebo for 16 weeks to see if it reduces symptoms like exercise intolerance and prevents the heart damage from worsening. The main goal is to see if the treatment improves the heart's pumping ability and stops progression toward heart failure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute for experimental and translational cardiovascular imaging
Frankfurt am Main, Hesse, 60596, Germany
-
University Hospital Greifswald
Greifswald, 17475, Germany
-
University Hospital Schleswig-Holstein, Campus KIEL
Kiel, 24105, Germany
-
University Hospital Ulm
Ulm, 89081, Germany
-
University Medical Centre Vienna
Vienna, 1090, Austria
Conditions
Explore the condition pages connected to this study.